Curcumin-encapsulated polymeric nanoparticles for metastatic osteosarcoma cells treatment

Abstract

Osteosarcoma is a high-class malignant bone cancer with a less than 20% five-year survival rate due to its early metastasis potential. There is an urgent need to develop a versatile and innoxious drug to treat metastatic osteosarcoma. Curcumin (Cur) has shown its potential for the treatment of many cancers; however, the clinical implication of native curcumin is severely hindered by its intrinsic property. In this study, a mixed system of monomethoxy (polyethylene glycol)-poly(d, l-lactide-co-glycolide)/poly(ε-caprolactone) (mPEG-PLGA/PCL) was used to build a formulation of curcuminencapsulated nanoparticles (Cur-NPs), which significantly improved the solubility, stability and cellular uptake of curcumin. Moreover, the Cur-NPs were superior to free curcumin in the matter of inhibition on the proliferation, migration and invasion of osteosarcoma 143B cells. It was found that both free curcumin and Cur-NPs could decrease the expressions of c-Myc and MMP7 in the level of mRNA and protein, which explained why free curcumin and Cur-NPs could inhibit the proliferation and invasion of metastatic osteosarcoma 143B cells. The Cur-NPs provided a promising strategy for metastatic osteosarcoma treatment.

Nanostructured system based on hydroxyapatite and curcumin: A promising candidate for osteosarcoma therapy

“…Curcumin has been demonstrated to have anti-neoplastic properties and cell proliferation inhibition in tumoural cells [23,24]. It is described that the viability of human osteosarcoma cells U2OS was reduced upon curcumin treatment [97].…”

“…Curcumin inhibited the growth of all osteosarcoma cell lines in addition to inhibiting their migration [23]. Wang et al [24] demonstrated that free curcumin and its encapsulated form in a mixed system of biopolymers were able to inhibit the proliferation, migration, and invasion of osteosarcoma cells. Furthermore, suggest that curcumin has the potential to be a new chemotherapeutic agent in the treatment of osteosarcoma.…”

Autophagy inhibitor-loaded mesoporous AgNPs@SiO2 nanoplatform for synergistically enhanced glioma radiotherapy

“…4c, the combination of 3-MA@Ag@MSNs and RT killed all cells in the group. Specifically, transwell invasion assay was performed to evaluate the antimigration effect of combination therapy [39] (Fig. 4d).…”

The Multifaceted Therapeutic Mechanisms of Curcumin in Osteosarcoma: State-of-the-Art

“…Several approaches have been pursued to overcome barriers to using curcumin since the solubility of curcumin in water is very low and the rate of degradation in an alkaline state is very high. The use of delivery systems such as hydrogels, liposomes, dendrimers, and micro-/nanoparticles to encapsulate the hydrophobic curcumin in its hydrophobic core has been investigated [ 88 ]. The amphiphilic peptide C18GR7RGDS is a nanoparticle carrier of curcumin in an aqueous solution with self-assembly characteristics in water and phosphate-buffered saline that shows a selective cytotoxicity effect against osteosarcoma cells compared to normal cells.…”

“…Curcumin encapsulated in natural biodegradable polyphenol hydrophilic copolymer y (polyethylene glycol)-poly(D,L-lactide-co-glycolide)/poly( ε -caprolactone) (mPEGPLGA/PCL) and (polyvinyl alcohol-polyethylene glycol − PVA-PEG) showed a synergic cytotoxic and anti-proliferation effect in osteosarcoma cells by decreasing the expression of CMYC, as a major protooncogene. Furthermore, this formulation can decrease the expression levels of MMP7, which correlates with metastatic features in cancers, thus preventing the invasion of osteosarcoma cells [ 88 , 97 ].…”